Ideaya Biosciences (IDYA) said Thursday it launched a phase 1/2 expansion in a clinical trial of its experimental IDE397 treatment in combination with Gilead Sciences' (GILD) Trodelvy in methylthioadenosine phosphorylase, or MTAP-deletion urothelial cancer, based on preliminary safety and clinical efficacy data.
The prevalence of MTAP-deletion is estimated at 26% in the cancer type, the company said. An update on the program is planned later this year.
Ideaya said it is the study sponsor, while Gilead will supply Trodelvy.
Ideaya shares were up 4.4% in recent premarket activity, while Gilead rose 1.4%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.